Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV)

Biologicals

Volumn 33, Issue 1, 2005, Pages 17-27

  Rezapkin, Gennady ^a   Dragunsky, Eugenia ^a   Chumakov, Konstantin ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BIOTIN; D ANTIGEN; IMMUNOGLOBULIN G; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; RABBIT ANTISERUM; REAGENT; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

ACCURACY; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; LINEAR REGRESSION ANALYSIS; NONHUMAN; OPTICAL DENSITY; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; RABBIT; REGRESSION ANALYSIS; SEROTYPE; SERUM; VALIDATION PROCESS;

ORYCTOLAGUS CUNICULUS; POLIOVIRUS; RNA VIRUSES;

EID: 13844298312     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2004.11.003     Document Type: Article

References (14)

1. A.J. Beale, and P.J. Mason The measurement of the D-antigen in poliovirus preparations J Hygiene 60 1962 113 121
2. P. van der Marel, A.G. Hazendonk, and A.L. van Wezel D-antigen determination in polio vaccine production: comparison of gel diffusion and ELISA methods Dev Biol Stand 47 1981 101 108
3. S. Abe, A. Yamaki, Y. Doi, and I. Yoshioka Effects of arildone on the immunogenicity of formalin-inactivated polioviruses Jpn J Med Sci Biol 40 1987 1 13
4. P.D. Minor, M. Ferguson, K. Katrak, D. Wood, A. John, and J. Howlett Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1 J Gen Virol 71 Pt 11 1990 2543 2551
5. L.A. Sawyer, J. McInnis, and P. Albrecht Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains Biologicals 21 1993 169 177
6. D.J. Wood, A.B. Heath, and L.A. Sawyer A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines Biologicals 23 1995 83 94
7. L.A. Sawyer, D.J. Wood, M. Ferguson, R. Crainic, E.C. Beuvery, and J. McInnis Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site Biologicals 25 1997 299 306
8. Y. Doi, S. Abe, H. Yamamoto, H. Horie, H. Ohyama, and K. Satoh Progress with inactivated poliovirus vaccines derived from the sabin strains Dev Biol (Basel) 105 2001 163 169
9. E.A. Cherkasova, E.A. Korotkova, M.L. Yakovenko, O.E. Ivanova, T.P. Eremeeva, and K.M. Chumakov Long-term circulation of vaccine-derived poliovirus that causes paralytic disease J Virol 76 2002 6791 6799
10. Pediarix - a combined vaccine for infants Med Lett Drugs Ther 45 2003 37 38
11. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants MMWR Morb Mortal Wkly Rep 52 2003 203 204
12. S. Partridge, and S.H. Yeh Clinical evaluation of a DTaP-HepB-IPV combined vaccine Am J Manag Care 9 2003 S13 S22
13. M.E. Pichichero, and L. Stonehocker Quick Clinical evaluation of Pediarix: a new pediatric combination vaccine Clin Pediatr (Phila) 42 2003 393 400
14. WHO Progress toward global eradication of poliomyelitis, 2002 MMWR Morb Mortal Wkly Rep 52 2003 366 369